Testing three medications together for newly diagnosed blood cancer

Plain-English translation of NCT06082934 on ClinicalTrials.gov ↗ · Source last updated October 2023 · Translation generated July 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a new treatment approach for a type of blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study combines three medications—olverembatinib, venetoclax, and dexamethasone—to see if they can work together to put the cancer into remission. This is a 'chemotherapy-free' approach, meaning it uses targeted medications instead of traditional chemotherapy drugs.

Currently, patients with newly diagnosed Ph+ ALL typically receive intensive chemotherapy along with other drugs. Researchers are exploring whether this new three-drug combination might be equally effective while potentially causing fewer side effects and being easier for patients to tolerate.

Do you qualify?

You likely qualify if…

you have been newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia
you are 18 years of age or older
you have adequate liver, kidney, and heart function
you have a life expectancy of more than 3 months
you are willing to use effective birth control during and for 120 days after treatment if you can become pregnant

You likely don't qualify if…

you are currently taking other investigational medications or participating in another drug trial
you are pregnant, breastfeeding, or have a positive pregnancy test
you have had major surgery within the past 3 weeks
you have a known or suspected HIV infection or active hepatitis
you have severe lung disease or difficulty swallowing that would interfere with taking oral medications

What participation looks like

You would take three medications as part of this treatment plan: one pill every other day, a daily pill that starts at a low dose and gradually increases over two weeks, and an intravenous infusion for the first month. You would receive close medical monitoring throughout your treatment to check how well the medication is working and to watch for any side effects. The trial aims to enroll 30 patients and will track how many patients achieve remission, whether cancer cells disappear completely at the genetic level, and your overall health and quality of life during treatment.

AI-generated summary from trial data · Jul 18, 2026 · Not medical advice

Trial locations(1 site)

China

Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shannxi